Collegium Pharmaceutical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021
May 06, 2021 at 02:08 pm EDT
Share
Collegium Pharmaceutical, Inc. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced operating income was USD 21.192 million compared to USD 5.061 million a year ago. Net income was USD 15.662 million compared to USD 450,000 a year ago. Basic earnings per share from continuing operations was USD 0.45 compared to USD 0.01 a year ago. Diluted earnings per share from continuing operations was USD 0.41 compared to USD 0.01 a year ago.
Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
COLLEGIUM PHARMACEUTICAL, INC. 
